The Latest

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Pfizer’s deal with Innovent is the sixth partnership involving China-originated drugs since last July that involves at least $8 billion in total proceeds, according to BioPharma Dive data.

    Updated 15 hours ago
  • ClipArt
    Image attribution tooltip
    Permission granted by Thermo Fisher Scientific
    Image attribution tooltip
    Sponsored by Thermo Fisher Scientific

    Process intensification: Separating fact from fiction

    Uncover four key misconceptions that could be holding your intensification strategies back — and how to set your initiatives up for success.

  • A 3D illustration of the hepatitis B virus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

    The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

  • A pill bottle for Eli Lilly's oral weight loss medication Foundayo
    Image attribution tooltip
    Courtesy of Eli Lilly
    Image attribution tooltip
    Obesity drugs

    CVS obesity drug deal puts Lilly on equal footing with Novo

    The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. 

  • A horizontal headshot of Simeon George, CEO of SR One.
    Image attribution tooltip
    Permission granted by SR One
    Image attribution tooltip
    Q&A // China competition

    SR One’s Simeon George on how China is rewriting biotech’s venture playbook

    The veteran investor says that the trove of ready-made prospects is making the global biotech ecosystem “more competitive” and steering dollars away from “half-baked ideas.”

  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Kailera’s three-pronged obesity shot shows promise in early trial

    As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.

  • A woman smiles at the camera.
    Image attribution tooltip
    Permission granted by Verge Genomics
    Image attribution tooltip
    Emerging biotech

    Verge, following trial failure, rebrands its AI drug discovery ambitions

    Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to patients who best benefit from them.

  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Cardio drugmaker Kardigan plans to go public

    Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    RA Capital Management is investing $30 million in Secretome Therapeutics, a company developing a new kind of cell therapy for the heart muscle weakness associated with Duchenne muscular dystrophy.

    Updated May 28, 2026
  • An Eli Lilly logo is seen at the top of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    Lilly dives into vaccine research with 3 biotech buyouts

    Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

  • single science glass flask with double exposure scientist holding tube in chemistry blue laboratory with stock market information background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Apogee eczema drugs gets Blackstone backing, heads to Phase 3

    The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA delays decision on AstraZeneca breast cancer pill

    The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in what would be a new kind of treatment setting.

    FDA
  • The headquarters of Eli Lilly & Co. is pictured on Aug. 1, 2019, in Indianapolis, Indiana.
    Image attribution tooltip
    "Eli Lilly Corporate Center, Indianapolis, Indiana, USA" by Momoneymoproblemz is licensed under CC BY-SA 4.0
    Image attribution tooltip
    Gene editing

    Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

    The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine

    The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.

  • A Bristol Myers Squibb employee works in one of the company's labs.
    Image attribution tooltip
    Permission granted by Bristol Myers Squibb
    Image attribution tooltip
    Q&A // Brain drug revival

    In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

    Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Kardigan, a startup run by former MyoKardia executives, outlined an offering that would support development of heart drugs licensed from Bristol Myers, Sanofi and Ionis Pharmaceuticals.

    Updated May 27, 2026
  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly’s triple-acting obesity drug hits goal in Phase 3 trial

    Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.

  • Brain pipette
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Parkinson’s drug from Biogen, Denali comes up short

    High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.

    Updated May 22, 2026
  • The Nasdaq MarketSite is seen on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    RA Capital banks $75M for a biotech SPAC

    Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.

  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers deepens AI investment with Anthropic deal

    The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-day activities.

  • Mathai Mammen, CEO, Parabilis Medicines
    Image attribution tooltip
    Permission granted by Parabilis
    Image attribution tooltip
    IPO window

    After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets

    Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.

  • A white office building bearing a sign for BioMarin Pharmaceutical stands against a blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioMarin notches win in study that could expand use of top-selling medicine

    The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.

  • A person points to a CT scan of the lungs using a pen.
    Image attribution tooltip
    Vadym Plysiuk via Getty Images
    Image attribution tooltip
    Startup launches

    Oorja, run by Acceleron veterans, launches to make new fibrosis drugs

    The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly snaps up Engage to advance non-viral genetic medicines

    The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

    Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.

  • People seen walking down Wall Street.
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    A migraine drugmaker heads to the public markets through reverse merger

    Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.